Positive Topline Results For Mutant Solid Tumors Reported By Major Medical Company
Immuneering's Breakthrough: Positive Phase 1 Trial Results for IMM-1-104 in RAS-Mutant Solid Tumors.
In a significant development in the fight against cancer, Immuneering Corporation (Nasdaq: IMRX) recently announced positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in patients with RAS-mutant solid tumors. This news is especially pertinent for those affected by RAS-mutant cancers, as the successful development of IMM-1-104 could offer a new treatment option where few currently exist. $Immuneering(IMRX.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
